Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
about
Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studiesNeurotrophic Effects of Mu Bie Zi (Momordica cochinchinensis) Seed Elucidated by High-Throughput Screening of Natural Products for NGF Mimetic Effects in PC-12 Cells.Chronic sciatic nerve compression induces fibrosis in dorsal root gangliaMycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcerAngiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials.Skeletal complications in cancer patients with bone metastases.Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia - A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) ReceptInflammatory Renin-Angiotensin System Disruption Attenuates Sensory Hyperinnervation and Mechanical Hypersensitivity in a Rat Model of Provoked Vestibulodynia.The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.
P2860
Q35786784-8C589612-2597-45E3-99CC-314BF373FB51Q36145445-6BB8AE34-9309-4127-AA7D-BE567867F1DDQ36624089-49E4AEF6-3262-49D1-BB61-50B1D76B28BFQ37115277-CA64FD8E-B7AC-47D7-BBAF-76474066E033Q37413252-2DD77A68-C716-42E6-A04A-CE1E98E6E7F4Q38260195-D85D1D6C-7FC8-452B-A009-34A2FE62A302Q38725329-8D737418-22EE-4EFE-87BC-8276909ED697Q38917438-DD9D11CA-4EDD-413F-A991-BC307A594A64Q41451854-3F4C0ABB-D9EB-40EC-ADE9-4F586229DC08Q47159630-214CCA28-9B23-4797-85E7-5935BC77E10BQ47385473-641E5AE9-D88C-45B7-BFA9-424DF45D62D2Q54977077-2D1F701C-907B-4086-8CCC-54518ABF8E3A
P2860
Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@en
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@nl
type
label
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@en
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@nl
prefLabel
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@en
Analgesic efficacy and mode of ...... tate cancer-induced bone pain.
@nl
P2860
P50
P356
P1433
P1476
Analgesic efficacy and mode of ...... state cancer-induced bone pain
@en
P2093
Bruce D Wyse
P2860
P304
P356
10.1111/PME.12258
P577
2013-10-30T00:00:00Z